Promising new combo offers hope for stomach cancer patients who fail immunotherapy
NCT ID NCT07392346
First seen Feb 06, 2026 · Last updated May 24, 2026 · Updated 21 times
Summary
This study is for people with advanced stomach cancer that has spread and no longer responds to first-line immunotherapy. It tests a new combination of three drugs: a targeted therapy (fruquintinib), a chemotherapy (nab-paclitaxel), and a novel immunotherapy (iparomlimab and tuvonralimab injection). The goal is to see if this combination can shrink tumors or slow cancer growth. About 68 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER ADENOCARCINOMA METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chinese PLA General Hospital, Beijing
RECRUITINGBeijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.